Innovent Biologics, Inc. (Stock Code: 1801) announced a strategic collaboration with Eli Lilly and Company (Lilly) aimed at advancing novel oncology and immunology treatments on a global scale. According to the announcement, this marks the seventh partnership between the two entities and is designed to leverage complementary strengths in antibody technology platforms and cross-border clinical capabilities.

Under the agreement, Innovent will lead the development of programs from initial concept to Phase 2 clinical trial completion in China. Outside of Greater China, Lilly holds the exclusive worldwide license to further develop and commercialize these products, while Innovent retains rights in Greater China. The collaboration includes an upfront payment of US$350 million to Innovent, with additional development, regulatory, and commercial milestone payments of up to approximately US$8.5 billion contingent upon future achievements. Innovent is also eligible for tiered royalties on net sales of each product outside Greater China.

The structure of this partnership creates what was described in the announcement as a highly efficient model for cross-border synergy. It highlights Innovent’s established research and development platforms while drawing on Lilly’s global scale and commercial experience. The ultimate aim is to accelerate the global availability of new treatment options for patients in oncology and immunology.